Comprehensive Stock Comparison
Compare OS Therapies Incorporated (OSTX) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | VRTX | Beta 0.44 vs OSTX's 0.81 |
| Dividends | OSTX | 100.0% yield; 1-year raise streak; VRTX pays no meaningful dividend |
| Momentum (1Y) | VRTX | +3.6% vs OSTX's -10.9% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs OSTX's -204.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
OS Therapies is a clinical-stage biopharmaceutical company developing novel treatments for osteosarcoma and other solid tumors. It aims to generate revenue through future drug sales and potential licensing deals — primarily from its lead candidate OST-HER2 (an off-the-shelf immunotherapy) and its tunable antibody-drug conjugate platform. The company's competitive advantage lies in its specialized focus on osteosarcoma — a rare pediatric cancer with limited treatment options — and its proprietary plug-and-play ADC technology with pH-sensitive linkers.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX leads in 4 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 1 category is tied.
Financial Metrics (TTM)
VRTX and OSTX operate at a comparable scale, with $11.7B and $0 in trailing revenue.
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $11.7B |
| EBITDAEarnings before interest/tax | -$19M | $4.2B |
| Net IncomeAfter-tax profit | -$18M | $3.7B |
| Free Cash FlowCash after capex | -$13M | $3.3B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +34.1% |
| Net MarginNet income ÷ Revenue | — | +31.3% |
| FCF MarginFCF ÷ Revenue | — | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.7% | +4.7% |
Valuation Metrics
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $49M | $126.2B |
| Enterprise ValueMkt cap + debt − cash | $43M | $124.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.83x | 32.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.91x |
| EV / EBITDAEnterprise value multiple | — | 26.63x |
| Price / SalesMarket cap ÷ Revenue | — | 10.52x |
| Price / BookPrice ÷ Book value/share | 37.81x | 6.87x |
| Price / FCFMarket cap ÷ FCF | — | 39.51x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-4 for OSTX. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs OSTX's 3/9, reflecting solid financial health.
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | +21.2% |
| ROA (TTM)Return on assets | -2.0% | +14.8% |
| ROICReturn on invested capital | — | +22.8% |
| ROCEReturn on capital employed | -7.5% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.20x |
| Net DebtTotal debt minus cash | -$6M | $3.7B |
| Cash & Equiv.Liquid assets | $6M | $5.1B |
| Total DebtShort + long-term debt | $0 | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | -2418.83x | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $23,616 today (with dividends reinvested), compared to $5,857 for OSTX. Over the past 12 months, VRTX leads with a +3.6% total return vs OSTX's -10.9%. The 3-year compound annual growth rate (CAGR) favors VRTX at 19.6% vs OSTX's -16.3% — a key indicator of consistent wealth creation.
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +9.7% | +9.9% |
| 1-Year ReturnPast 12 months | -10.9% | +3.6% |
| 3-Year ReturnCumulative with dividends | -41.4% | +71.1% |
| 5-Year ReturnCumulative with dividends | -41.4% | +136.2% |
| 10-Year ReturnCumulative with dividends | -41.4% | +481.2% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +19.6% |
Risk & Volatility
VRTX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than OSTX's 0.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 95.6% from its 52-week high vs OSTX's 57.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.44x |
| 52-Week HighHighest price in past year | $2.57 | $519.68 |
| 52-Week LowLowest price in past year | $1.12 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +57.2% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 54.6 |
| Avg Volume (50D)Average daily shares traded | 510K | 1.2M |
Analyst Outlook
OSTX is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | OSTXOS Therapies Inco… | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $545.08 |
| # AnalystsCovering analysts | — | 55 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $1.50 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 24 | Feb 26 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | 100 | 55.38 | -44.6% |
| Vertex Pharmaceutic… (VRTX) | 100 | 93.32 | -6.7% |
Vertex Pharmaceutic… (VRTX) returned +136% over 5 years vs OS Therapies Incorp… (OSTX)'s -41%. A $10,000 investment in VRTX 5 years ago would be worth $23,616 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | $0.00 | $0.00 | — |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~32x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | -0 | -0.52 | -74185.7% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 5Free Cash Flow — 5 Years
OS Therapies Incorporated generated $-7M FCF in 2024 (-65% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
OSTX vs VRTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OSTX or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 32.4x trailing P/E (25.7x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSTX or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +136.2%, compared to -41.4% for OS Therapies Incorporated (OSTX). A $10,000 investment in VRTX five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +481.2% versus OSTX's -41.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSTX or VRTX?
By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus OS Therapies Incorporated's 0.81β — meaning OSTX is approximately 83% more volatile than VRTX relative to the S&P 500.
04Which has better profit margins — OSTX or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 0.0% for OS Therapies Incorporated — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 0.0% for OSTX. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OSTX or VRTX?
In this comparison, OSTX (100.0% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.
06Is OSTX or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +481.2% 10Y return). Both have compounded well over 10 years (VRTX: +481.2%, OSTX: -41.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OSTX and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OSTX is a small-cap income-oriented stock; VRTX is a mid-cap quality compounder stock. OSTX pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.